Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26801060.
- Also identified by DOI 10.1016/j.athoracsur.2015.12.004 and PMC identifier 4987708.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The concept of gene therapy was introduced in the 1970s after the development of recombinant DNA technology. Despite the initial great expectations, this field experienced early setbacks. Recent years have seen a revival of clinical programs of gene therapy in different fields of medicine. There are many promising targets for genetic therapy as an adjunct to cardiac surgery. The first positive long-term results were published for adenoviral administration of vascular endothelial growth factor with coronary artery bypass grafting. In this review we analyze the past, present, and future of gene therapy in cardiac surgery. The articles discussed were collected through PubMed and from author experience. The clinical trials referenced were found through the Wiley clinical trial database (http://www.wiley.com/legacy/wileychi/genmed/clinical/) as well as the National Institutes of Health clinical trial database (Clinicaltrials.gov).
Medical subject headings
- Cardiac Surgical Procedures
- Clinical Trials as Topic
- Genetic Therapy